What it sells
Kagoshima startup developing medical products including CHITOSLA chitosan hydrogel wound dressings (CHITOSLA VX injectable chitosan hydrogel microparticles) and NasaPure nasal care products.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-23 | Series A | JPY 140M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-29.